N2OFF shares surge 15.76% premarket as MitoCareX reports positive in vitro anti-inflammatory drug data.

N2OFF Inc. surged 15.76% in premarket trading following preliminary in vitro data from its subsidiary MitoCareX Bio, which demonstrated that MITOLINE™-derived small-molecule candidates reduced pro-inflammatory markers in human immune cells. The results validate mitochondrial carrier modulation as a potential therapeutic approach for inflammatory metabolic diseases, a market projected to exceed $120 billion by 2030. The news underscores MitoCareX’s progress in overcoming a key drug discovery bottleneck via its algorithmic platform and positions the company to advance candidates toward pre-clinical studies. The stock’s sharp rise aligns with the announcement’s implications for future revenue potential in a high-growth sector, overshadowing broader financial challenges highlighted in other reports.